ARAMIS Follow-Up: PSA Levels, Radiological Progression in nmCRPC

Alicia Morgans, MD, MPH, of Dana-Farber Cancer Institute, sits down with Christopher Wallis, MD, PhD, FRCSC, of University of Toronto, to dissect the association between prostate-specific antigen level of less than 0.2 ng/mL and risk of radiological progression in patients with nonmetastatic castration-resistant prostate cancer.

This data was presented as a follow-up analysis of the ARAMIS study at the 2024 American Society of Clinical Oncology Annual Meeting.